Pathophysiology of ACNE VULGARIS
Fighting with bacteria, decreasing the production of oil by the sebaceous glands, unplugging clogged follicular canals…
Why all these approaches are not effective? Maybe current paradigm of acne treatments is not completely correct? Resting mast cells are always physically located adjacent to the skin epidermis. Their role is patrolling i.e. an observation and the maintenance of security of skin barrier. Their pattern recognition molecules allow them to readily recognize and rapidly respond to bacteria, allergens and other pathogens that breach the skin barrier. However, MC itself can’t fight with pathogens, they can only send alarm signals that recruit other immune cells that will fight with the invasion.
Our working hypothesis: activated mast cells are the first chain link of the inflammation process. Novel drug that stops C. acnes proliferation and simultaneously interruptsmast cells activation is needed.
OUR Solution For acne vulgaris
Our solution is a new transdermal non-steroidal mutual prodrug that targets the roots of the inflammation process: bacteria and activated mast cells. Our mutual prodrug CromAzol is specially designed to fight Acne vulgaris.
CromAzol is a first-in-class topical formulation that target 4 main factors that lead to severe acne: 1) clogged comedones (pilosebaceous ducts); 2) an overgrowth of C. acnes bacteria in clogged comedones; 3) activated mast cells that send alarm signals and recruit other innate immune cells to acne lesions; 4) neutrophils infiltrated in acne lesions and induced tissue damage by oxygen radicals.
All component active drugs of mutual prodrug are safe and effective, with minimal side effects when delivered subcutaneously via topical formulation.
We have completed in vitro studies and are now preparing for studies in animal models. PCT application of patent “MUTUAL PRODRUGS OF CROMOGLICIC ACID” was filed May-16-2023, Application No.: PCT/US2023/067055
And his commentary here
